Download - UCB: INNOVATION FOR SPECIALISTS
May 2005 - 1
UCB: INNOVATION FOR SPECIALISTS
UBS – Global Healthcare ConferenceNew York - May 24, 2005
Roch Doliveux - CEO
May 2005 - 2
DISCLAIMER
This presentation contains elements that are not historical facts, including,
without limitation, certain statements on future expectations and other
forward looking statements. Such statements are based on management's
current views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or events to differ
materially from those anticipated.
May 2005 - 3
389815382
0
100
200
300
400
UCB Pharma (12 months,Continuingbusiness)
Celltech (5 months,
consolidatedexcluding fair
valueadjustment)
Celltech(7 months, Jan-Jul)
Proforma2004
UCB Biopharma Financial highlights 2004
EBITA
2.124239
216
1.669
0
500
1.000
1.500
2.000
2.500
UCB Pharma (12 months,Continuingbusiness)
Celltech (5 months,
consolidated)
Celltech (7 months,
Jan-Jul)
Proforma2004
€m€m
Revenue
( )
Pro-forma according to IFRS
May 2005 - 4
UCB Biopharma Strengths
Leading, global, dynamic Biopharmaceutical company with presence in over
40 countries
Leader in the fields of epilepsy, allergy, and monoclonal antibody research
Proven productivity in research with several potential blockbusters in
pipeline
Strong partnerships
May 2005 - 5
Global Presence
Net Sales in 2004: € 1.7 billion
Europe
40%
United States
40%
Japan12%
ROW8%
Net sales excluding royalties and fees
May 2005 - 6
2004 Revenues, € billion
A Biopharmaceutical leader
• Amgen
• Schering AG
• Novo Nordisk
• Genentech
• UCB
• Altana
• Serono
• Genzyme
1.8
1.8
• Chiron
• Lundbeck
1.4
1.3
• Biogen IDEC 1.8
8.5
4.9
3.9
3.7
2.1
2.1
Revenues 2004 (€ billion)
May 2005 - 7
UCB Biopharma Strengths
Leading, global, dynamic Biopharmaceutical company with presence in over
40 countries
Leader in the fields of epilepsy, allergy, and monoclonal antibody research
Proven productivity in research with several potential blockbusters in
pipeline
Strong partnerships
May 2005 - 8
CENTRAL NERVOUS SYSTEM
May 2005 - 9
US Sales of $ 335 million in 2004 (+ 42%)
Most successful anti-epileptic launch ever
Market leader in the US
Filed intravenous formulation (Q4 2004)
Paediatric priority review (Q4 2004)
Expected filings end 2005:
monotherapy
juvenile myoclonic epilepsy
generalised seizures
US Sales of $ 335 million in 2004 (+ 42%)
Most successful anti-epileptic launch ever
Market leader in the US
Filed intravenous formulation (Q4 2004)
Paediatric priority review (Q4 2004)
Expected filings end 2005:
monotherapy
juvenile myoclonic epilepsy
generalised seizures
12
16
17
22
23Keppra (UCB)
Lamictal (GSK)
Topamax (J&J)
Trileptal (Novartis)
Neurontin (Pfizer)
U.S. Epilepsy Rx market share, %
(Source: Rx data from IMS, MAT Q3/2004)
2004 – Sales of € 417 million (+ 33%)
May 2005 - 10
Strong Growth US NRx
NRx Prescriptions: Weekly Data – week ending April 15, 2005
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
3-Jan
3-Feb
3-Mar
3-Apr
3-May
3-Jun
3-Jul
3-Aug
3-Sep
3-Oct
3-Nov
3-Dec
2003 2004 2005
May 2005 - 11
A L L E R G Y
May 2005 - 12
Turnover 2004 * € 1,447 million
* UCB consolidates € 544 million
Turnover Q1 2005 * $342 million in US (+14% vs. Q1 2004)
Partnerships with Pfizer (USA)
Dai-ichi (Japan)
GSK (Japan)
Turnover 2004 * € 1,447 million
* UCB consolidates € 544 million
Turnover Q1 2005 * $342 million in US (+14% vs. Q1 2004)
Partnerships with Pfizer (USA)
Dai-ichi (Japan)
GSK (Japan)
World’s leading antihistamine
May 2005 - 13
Launched in Europe in February 2001
Only antihistamine approved for persistent rhinitis in Europe
Turnover * € 104 million (+ 156%) in 2004
* 41% growth in Europe for 1Q 2005
Xyzal sales now exceed Zyrtec’s sales in Europe
Launched in Europe in February 2001
Only antihistamine approved for persistent rhinitis in Europe
Turnover * € 104 million (+ 156%) in 2004
* 41% growth in Europe for 1Q 2005
Xyzal sales now exceed Zyrtec’s sales in Europe
Leader in 5 European countries
May 2005 - 14
UCB Biopharma Strengths
Leading, global, dynamic Biopharmaceutical company with presence in over
40 countries
Leader in the fields of epilepsy, allergy, and monoclonal antibody research
Proven productivity in research with several potential blockbusters in
pipeline
Strong partnerships
May 2005 - 15
Therapeutic Areas
CNS
• Epilepsy• Pain• Migraine• Movement disorders
Inflammation & auto-immune disease
• Rheumatoid arthritis (RA)• Irritable bowel diseases (IBD)• Crohn’s disease (CD)• Allergy• Respiratory disease• Systemic Lupus Erythematosus (SLE)• Psoriasis
Inflammation in CNS• Multiple Sclerosis (MS)
OncologyOncology• Lung cancer & leukaemiaLung cancer & leukaemia
May 2005 - 16
Pragmatic Low Risk Approach to R&D
Drug candidate
identification and
optimization
Clinical development
Potential disease targets
Preclinical pharmacology
and toxicology
Successful therapy
Validated targets
Anti-allergy Atarax Zyrtec Xyzal Efleterizine
Well-known chemical/biological families
Proven clinical safety and efficacy
Anti TNF Remicade Cimzia
Anti VEGF Avastin CDP791
Cerebral
Disorders Nootropil Keppra Brivara/Selectracetam
May 2005 - 17
Strong new product pipeline
2005 2006 2007 2008 2009 2010
• Xyrem
• Equasym XL
• Kentera
• Xyzal syrup• Keppra
paediatric/ IV
• CIMZIA (Crohn’s)
• CIMZIA (RA)• Keppra
mono-therapy/PGS
• Brivaracetam• Seletracetam
• CDP791• CMC544• Efletirizine
• CDP435• CDP323• UCB101264
Large molecule
Small molecule
Large molecule
Small molecule
Expected product launches
May 2005 - 18
C I M Z I A
May 2005 - 19
TNFα inhibitors market is fast growing
Sources: IMS World Review 2003 and Evaluate pharma
Market value (MAT 12/04) $5.3 billion
Annual Growth + 44%
Estimated Market Value (2009) = $13 billion
CAGR (2003-2009) + 23%
May 2005 - 20
Cimzia – only one competitor in Crohn’s Disease
• CD market $1 billion
• Remicade only anti-TNF
Source: Decision Resource Reports October 2003/2004
* 2003 Total Crohn’s disease in G7 market
May 2005 - 21
Cimzia – Key development milestones
Crohn’s disease
Clinical results Q3 2005
Filing End 2005 / Early 2006
Pre-launch Ongoing
Launch 1H 2007
Rheumatoid arthritis
Clinical results 2H 2006
Filing 1H 2007
Pre-launch Ongoing
Launch End 2007 / Early 2008
May 2005 - 22
UCB Biopharma Strengths
Leading, global, dynamic Biopharmaceutical company with presence in over
40 countries
Leader in the fields of epilepsy, allergy, and monoclonal antibody research
Proven productivity in research with several potential blockbusters in
pipeline
Strong partnerships
May 2005 - 23
Strong partnerships
Upstream AmgenAstra ZenecaBiogen IdecJohnson & JohnsonMillennium
Downstream Dai-ichiGSKPfizerOrphan MedicalWatson PharmaceuticalsWyeth
May 2005 - 24
C O N C L U S I O N
• Financial outlook
• Priorities 2005
• Vision
May 2005 - 25
Financial outlook for 2005
Biopharma growth expected to offset Surface Specialty/ Films contribution
Substantial capital gain resulting from sale of Surface Specialties
Accelerated investment in Cimzia (CD and RA) development program
Net income 2005 in line with 2004 (IFRS) excluding capital gains of 2004 (Films)
and 2005 (Surface Specialties)
May 2005 - 26
Priorities for 2005
• Maximize Keppra & post Keppra franchise
• Make Cimzia a success
• Optimize the allergy franchise transition
• Innovate to secure long-term growth
• Deliver on improvement plans
May 2005 - 27
UCB Vision - Innovation for Specialists
To build a global biopharmaceutical leader,
based on unique blend of innovation,
entrepreneurship and proven experience,
bringing to specialists first,
new medicines to heal patients
suffering from severe diseases